Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W.

PLoS One. 2012;7(4):e35309. doi: 10.1371/journal.pone.0035309. Epub 2012 Apr 20.

2.

Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.

Lyu J, Wu Y, Li C, Wang R, Song H, Ren G, Guo W.

J Oral Pathol Med. 2016 Apr;45(4):295-301. doi: 10.1111/jop.12358. Epub 2015 Sep 24.

PMID:
26399561
3.

BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.

Öztürk Sari Ş, Yilmaz İ, Taşkin OÇ, Narli G, Şen F, Çomoğlu Ş, Firat P, Bİlgİç B, Yilmazbayhan D, Özlük Y, Büyükbabanİ N.

Pathology. 2017 Jan;49(1):55-61. doi: 10.1016/j.pathol.2016.09.065. Epub 2016 Nov 30.

PMID:
27914687
4.

[ Spectrum of oncogene mutations is different in melanoma subtypes].

Mazurenko NN, Tsyganova IV, Lushnikova AA, Ponkratova DA, Anurova OA, Cheremushkin EA, Mikhailova IN, Demidov LV.

Mol Biol (Mosk). 2015 Nov-Dec;49(6):1022-9. doi: 10.7868/S0026898415060166. Russian.

PMID:
26710785
5.

Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.

Tseng D, Kim J, Warrick A, Nelson D, Pukay M, Beadling C, Heinrich M, Selim MA, Corless CL, Nelson K.

J Am Acad Dermatol. 2014 Aug;71(2):229-36. doi: 10.1016/j.jaad.2014.03.033. Epub 2014 May 17.

6.

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.

Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG.

Semin Cutan Med Surg. 2012 Dec;31(4):267-73. doi: 10.1016/j.sder.2012.07.007.

PMID:
23174497
7.

Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.

Ponti G, Pellacani G, Tomasi A, Loschi P, Luppi G, Gelsomino F, Longo C.

Dis Markers. 2014;2014:671283. doi: 10.1155/2014/671283. Epub 2014 Jan 23. Erratum in: Dis Markers. 2014;2014:246751. Giovanni, Ponti [corrected to Ponti, Giovanni]; Giovanni, Pellacani [corrected to Pellacani, Giovanni]; Aldo, Tomasi [corrected to Tomasi, Aldo]; Pietro, Loschi [corrected to Loschi, Pietro]; Gabriele, Luppi [corrected to Luppi, Gabriele]; Fabio, Gelsomino [corrected to Gelsomino, Fabio]; Caterina, Longo [corrected to Longo, Caterina].

8.

Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.

Yaman B, Akalin T, Kandiloğlu G.

Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.

PMID:
25357015
9.

Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.

Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragón E, Micalessi I, Frans J, Noten V, Bourgain C, Vriesema R, van der Geize R, Cokelaere K, Vercooren N, Crul K, Rüdiger T, Buchmüller D, Reijans M, Jans C.

Exp Mol Pathol. 2015 Dec;99(3):485-91. doi: 10.1016/j.yexmp.2015.09.004. Epub 2015 Sep 25.

PMID:
26407762
10.

Mutation stability in primary and metastatic melanoma: what we know and what we don't.

Varada S, Mahalingam M.

Histol Histopathol. 2015 Jul;30(7):763-70. doi: 10.14670/HH-11-584. Epub 2015 Jan 13. Review.

PMID:
25585249
11.

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.

Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB.

J Cutan Pathol. 2012 Sep;39(9):821-5. doi: 10.1111/j.1600-0560.2012.01950.x. Epub 2012 Jul 19.

12.

[Translational research and diagnostics of melanoma].

Rüschoff J, Kleinschmidt M, Middel P.

Pathologe. 2012 Nov;33 Suppl 2:291-5. doi: 10.1007/s00292-012-1661-1. Review. German.

PMID:
22968732
13.

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.

Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ.

Diagn Mol Pathol. 2012 Mar;21(1):1-8. doi: 10.1097/PDM.0b013e31823b216f.

PMID:
22306669
14.

The molecular profile of metastatic melanoma in Australia.

Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV.

Pathology. 2016 Feb;48(2):188-93. doi: 10.1016/j.pathol.2015.12.008. Epub 2016 Jan 18.

PMID:
27020391
15.

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.

PLoS One. 2012;7(7):e40439. doi: 10.1371/journal.pone.0040439. Epub 2012 Jul 10.

16.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R.

Ann Oncol. 2014 May;25(5):959-67. doi: 10.1093/annonc/mdu049. Epub 2014 Feb 6.

17.

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.

Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, Völker B, Schacht V, Timmermann B, Gutzmer R.

Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634.

18.

BRAF and GNAQ mutations in melanocytic tumors of the oral cavity.

Cohen Y, Goldenberg-Cohen N, Akrish S, Shani T, Amariglio N, Dratviman-Storobinsky O, Kaplan I, Barshack I, Hirshberg A.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):778-84. doi: 10.1016/j.oooo.2012.09.001.

PMID:
23159116
19.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
20.

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.

Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P.

Br J Dermatol. 2013 Apr;168(4):708-16. doi: 10.1111/bjd.12140.

PMID:
23528057

Supplemental Content

Support Center